Form 4: Royalty Pharma Director Catherine Engelbert Receives Stock Award

Catherine Engelbert, a director at Royalty Pharma plc, was granted 7,614 Class A Ordinary Shares on May 13, 2025, as part of the company's 2020 Independent Director Equity Incentive Plan.

Summary

• On May 13, 2025, Catherine M. Engelbert, a director of Royalty Pharma plc, received an award of 7,614 Class A Ordinary Shares.
• The shares were granted under the Issuer's 2020 Independent Director Equity Incentive Plan.
• The restricted stock units are scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.
• Following the transaction, Engelbert beneficially owns 51,128 Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director interests with shareholders. There are no indications of negative sentiment.

Positives

• The stock award aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the restricted stock units.

Industry Context

Stock awards to directors are a common practice in publicly traded companies to incentivize and align their interests with those of shareholders. The size and terms of the award are typical for director compensation.

Comparison to Industry Standards

• Director compensation packages, including stock awards, vary significantly across the pharmaceutical industry.
• Companies like Pfizer, Johnson & Johnson, and Merck also utilize equity-based compensation for their directors.
• The specific value and vesting terms of these awards depend on factors such as company size, performance, and individual director responsibilities.
• Benchmarking against similar-sized royalty-focused companies would provide a more precise comparison.

Stakeholder Impact

• The stock award could have a minor positive impact on shareholder sentiment as it aligns director interests with those of the shareholders.

Key Dates

Keywords

Royalty Pharma, Director, Stock Award, Equity Incentive Plan, Beneficial Ownership, RPRX, Catherine Engelbert